Survey On Prevalence And Pharmacological Approaches In Non-Alcoholic Fatty Liver Disease And Steatohepatitis
DOI:
https://doi.org/10.52783/jns.v14.2947Keywords:
Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, NAFLD, Metabolic Syndrome, Pharmacological ManagementAbstract
Introduction: Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis have emerged as significant public health concerns, closely linked to metabolic syndrome. This study aimed to assess the prevalence, associated risk factors, and pharmacological approaches for managing NAFLD/NASH.
Material And Methods: A cross-sectional study was conducted on 191 adult patients diagnosed with NAFLD or NASH based on clinical assessments, laboratory parameters, and imaging findings. Data on demographics, comorbidities, pharmacological treatments, and biochemical markers were analyzed to evaluate disease severity and treatment patterns.
Results: NAFLD was most prevalent among middle-aged adults (40–50 years), with a male predominance. Obesity (46.07%) and overweight status (30.36%) were the most common risk factors. Fibroscan findings indicated that 49.73% of patients had moderate fibrosis, while 17.80% had severe fibrosis. Elevated aspartate aminotransferase(AST),alanine aminotransferase( ALT), and ferritin levels were significantly associated with fibrosis severity. Pharmacological management predominantly involved vitamin E (46.07%), atorvastatin (43.97%), metformin (25.65%), and GLP-1 receptor agonists (29.84%), reflecting a growing focus on metabolic modulation in NAFLD treatment.
Conclusion: The study reinforces the strong association between NAFLD and metabolic dysfunction. While no FDA-approved treatment exists, the current therapeutic landscape relies on insulin sensitizers, lipid-lowering agents, and antioxidants. Early diagnosis and intervention through metabolic control remain crucial in mitigating disease progression. Further research is warranted to establish standardized treatment guidelines and assess long-term outcomes of pharmacological interventions.
Downloads
Metrics
References
Guo, X., Yin, X., Liu, Z., & Wang, J. (2022). Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment. International Journal of Molecular Sciences, 23(24). https://doi.org/10.3390/ijms232415489
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012). The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 55(6), 2005-2023. https://doi.org/10.1002/hep.25762
Milić, S., Lulić, D., & Štimac, D. (2014). Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations. World Journal of Gastroenterology : WJG, 20(28), 9330-9337. https://doi.org/10.3748/wjg.v20.i28.9330
Leoni, S., Tovoli, F., Napoli, L., Serio, I., Ferri, S., & Bolondi, L. (2018). Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World Journal of Gastroenterology, 24(30), 3361-3373. https://doi.org/10.3748/wjg.v24.i30.3361
Han, S. K., Baik, S. K., & Kim, M. Y. (2023). Non-alcoholic fatty liver disease: Definition and subtypes. Clinical and Molecular Hepatology, 29(Suppl), S5. https://doi.org/10.3350/cmh.2022.0424
The Lancet Gastroenterology Hepatology. Redefining non-alcoholic fatty liver disease: what's in a name? Lancet Gastroenterol Hepatol. 2020 May;5(5):419. doi: 10.1016/S2468-1253(20)30091-1. PMID: 32277896.
Singh, S. P., Singh, A., Misra, D., Misra, B., Pati, G. K., Panigrahi, M. K., Kar, S. K., Bhuyan, P., Pattnaik, K., Meher, C., Agrawal, O., Rout, N., Swain, M., & Aich, P. (2015). Risk Factors Associated With Non-Alcoholic Fatty Liver Disease in Indians: A Case–Control Study. Journal of Clinical and Experimental Hepatology, 5(4), 295-302. https://doi.org/10.1016/j.jceh.2015.09.001
Kudaravalli P, John S. Nonalcoholic Fatty Liver. [Updated 2023 Apr 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541033/
Patell, R., Dosi, R., Joshi, H., Sheth, S., Shah, P., & Jasdanwala, S. (2013). Non-Alcoholic Fatty Liver Disease (NAFLD) in Obesity. Journal of Clinical and Diagnostic Research : JCDR, 8(1), 62-66. https://doi.org/10.7860/JCDR/2014/6691.3953
Amarapurkar, et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol. 2007;6:161–3.
Duseja A. Nonalcoholic fatty liver disease in India--is it different? Trop Gastroenterol. 2006;27(4):142–6.
Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in northern Italy. Ann Intern Med. 2000;132(2):112–7.
Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593–608. doi: 10.1016/j.jhep.2012.12.005.
Zhang, C., & Yang, M. (2021). Current Options and Future Directions for NAFLD and NASH Treatment. International Journal of Molecular Sciences, 22(14). https://doi.org/10.3390/ijms22147571
Mazo D.F., Malta F.M., Stefano J.T., Salles A.P.M., Gomes-Gouvea M.S., Nastri A.C.S., Almeida J.R., Pinho J.R.R., Carrilho F.J., Oliveira C.P. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population. Ann. Hepatol. 2019;18:466–471. doi: 10.1016/j.aohep.2018.10.004.
Kamm D.R., Pyles K.D., Sharpe M.C., Healy L.N., Colca J.R., McCommis K.S. Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide. J. Biol. Chem. 2021;296:100807. doi: 10.1016/j.jbc.2021.100807.
Smith U. Pioglitazone: Mechanism of action. Int. J. Clin. Pr. Suppl. 2001;121:13–18.
Panunzi S., Maltese S., Verrastro O., Labbate L., De Gaetano A., Pompili M., Capristo E., Bornstein S.R., Mingrone G. Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: A hierarchical network meta-analysis. Diabetes Obes. Metab. 2021;23:980–990. doi: 10.1111/dom.14304.
Kulkarni S., Huang J., Tycksen E., Cliften P.F., Rudnick D.A. Diet Modifies Pioglitazone’s Influence on Hepatic PPARγ-Regulated Mitochondrial Gene Expression. PPAR Res. 2020;2020:1–20. doi: 10.1155/2020/3817573.
Alshehri A.S., El-Kott A.F., El-Kenawy A.E., Khalifa H.S., AlRamlawy A.M. Cadmium chloride induces non-alcoholic fatty liver disease in rats by stimulating miR-34a/SIRT1/FXR/p53 axis. Sci.Total Environ. 2021;784:147182. doi: 10.1016/j.scitotenv.2021.147182.
Xu Y., Zhu Y., Hu S., Xu Y., Stroup D., Pan X., Bawa F.C., Chen S., Gopoju R., Yin L., et al. Hepatocyte Nuclear Factor 4α Prevents the Steatosis-to-NASH Progression by Regulating p53 and Bile Acid Signaling (in mice) Hepatology. 2021;73:2251–2265. doi: 10.1002/hep.31604.
Furuta K., Guo Q., Pavelko K.D., Lee J.-H., Robertson K.D., Nakao Y., Melek J., Shah V.H., Hirsova P., Ibrahim S.H. Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis. J. Clin. Investig. 2021;131:e143690. doi: 10.1172/JCI143690.
Carr R.M. VCAM-1: Closing the gap between lipotoxicity and endothelial dysfunction in nonalcoholic steatohepatitis. J. Clin. Investig. 2021;131:e147556. doi: 10.1172/JCI147556.
Van Dalem J., Driessen J.H., Burden A.M., Stehouwer C.D., Klungel O.H., de Vries F., Brouwers M.C. Thiazolidinediones and Glucagon-like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology. 2021 doi: 10.1002/hep.32012.
David D, Eapen CE. What are the current pharmacological therapies for nonalcoholic fatty liver disease?. Journal of Clinical and Experimental Hepatology. 2021 Mar 1;11(2):232-8.
Basaranoglu, M., & Neuschwander-Tetri, B. A. (2006). Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis. Gastroenterology & Hepatology, 2(4), 282-291. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335683/
Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202–1219.
Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol. 1999;94:1018–1022.
Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37:1202–1219.
Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286–1292.
Turlin B, Mendler MH, Moirand R, Guyader D, Guillygomarc’h A, Deugnier Y. Histologic features of the liver in insulin resistance-associated iron overload: a study of 139 patients. Am J Clin Pathol. 2001;116:263–270.
Bugianesi E, Manzini P, D’Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004;39:179–187.
Jacobs JE, Birnbaum BA, Shapiro MA, et al. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. Am J Roentgenology. 1998;171:659–664.
Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–750.
Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol. 2005;288:E462–468.
Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–1395.
Thomas EL, Hamilton G, Patel N, et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut. 2005;54:122–127.
Caldwell, S. (2017). NASH Therapy: Omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Clinical and Molecular Hepatology, 23(2), 103-108. https://doi.org/10.3350/cmh.2017.0103
Amanullah I, Khan YH, Anwar I, Gulzar A, Mallhi TH, Raja AA. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials. Postgrad Med J. 2019 Nov;95(1129):601–11. doi: 10.1136/postgradmedj-2018-136364.
Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol. 2011 Jan;106(1):71–7. doi: 10.1038/ajg.2010.299.
Zhang S, Ren X, Zhang B, Lan T, Liu B. A systematic review of statins for the treatment of nonalcoholic steatohepatitis: safety, efficacy, and mechanism of action. Molecules. 2024;29(8):1859. doi: 10.3390/molecules29081859.
Torres-Peña JD, Martín-Piedra L, Fuentes-Jiménez F. Statins in non-alcoholic steatohepatitis. Front Cardiovasc Med. 2021;8:777131. doi: 10.3389/fcvm.2021.777131.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
